首页> 外文期刊>Cancers >Circulating Tumor Cell Detection and Capture by Photoacoustic Flow Cytometry in Vivo and ex Vivo
【24h】

Circulating Tumor Cell Detection and Capture by Photoacoustic Flow Cytometry in Vivo and ex Vivo

机译:体内和体外通过光声流式细胞术检测和捕获循环肿瘤细胞

获取原文
           

摘要

Despite progress in detecting circulating tumor cells (CTCs), existing assays still have low sensitivity (1–10 CTC/mL) due to the small volume of blood samples (5–10 mL). Consequently, they can miss up to 103–104 CTCs, resulting in the development of barely treatable metastasis. Here we analyze a new concept of in vivo CTC detection with enhanced sensitivity (up to 102–103 times) by the examination of the entire blood volume in vivo (5 L in adults). We focus on in vivo photoacoustic (PA) flow cytometry (PAFC) of CTCs using label-free or targeted detection, photoswitchable nanoparticles with ultrasharp PA resonances, magnetic trapping with fiber-magnetic-PA probes, optical clearance, real-time spectral identification, nonlinear signal amplification, and the integration with PAFC in vitro. We demonstrate PAFC’s capability to detect rare leukemia, squamous carcinoma, melanoma, and bulk and stem breast CTCs and its clusters in preclinical animal models in blood, lymph, bone, and cerebrospinal fluid, as well as the release of CTCs from primary tumors triggered by palpation, biopsy or surgery, increasing the risk of metastasis. CTC lifetime as a balance between intravasation and extravasation rates was in the range of 0.5–4 h depending on a CTC metastatic potential. We introduced theranostics of CTCs as an integration of nanobubble-enhanced PA diagnosis, photothermal therapy, and feedback through CTC counting. In vivo data were verified with in vitro PAFC demonstrating a higher sensitivity (1 CTC/40 mL) and throughput (up to 10 mL/min) than conventional assays. Further developments include detection of circulating cancer-associated microparticles, and super-resolution PAFC beyond the diffraction and spectral limits.
机译:尽管在检测循环肿瘤细胞(CTC)方面取得了进展,但由于血液样本量很少(5-10 mL),现有的检测方法仍具有较低的灵敏度(1-10 CTC / mL)。因此,他们可能会错过多达10 3 –10 4 的CTC,从而导致难以治疗的转移发生。在这里,我们通过检查体内的全血量分析了一种具有更高灵敏度(高达10 2 –10 3 倍)的体内CTC检测的新概念(5 L(成人)。我们专注于使用无标记或靶向检测的CTC的体内光声(PA)流式细胞术(PAFC),具有超锐利PA共振的可光切换纳米颗粒,使用纤维-PA探针进行磁阱捕获,光学清除,实时光谱识别,非线性信号放大,以及与PAFC的体外整合。我们证明PAFC能够在临床前动物模型的血液,淋巴液,骨液和脑脊髓液中检测罕见的白血病,鳞状癌,黑色素瘤,大块和干乳腺CTC及其簇,以及从原发性肿瘤触发的CTC释放触诊,活检或手术会增加转移的风险。根据CTC的转移潜能,CTC的寿命作为内渗和外渗率之间的平衡在0.5–4 h的范围内。我们介绍了CTC的诊断学,将纳米气泡增强的PA诊断,光热疗法和通过CTC计数的反馈相结合。用体外PAFC验证了体内数据,证明了其灵敏度(1 CTC / 40 mL)和通量(高达10 mL / min)比常规测定更高。进一步的发展包括检测与癌症相关的循环中的微粒,以及超出衍射和光谱极限的超分辨率PAFC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号